Osmotica Pharmaceuticals plc to Provide Third Quarter 2020 Business and Financial Update on November 10, 2020
Osmotica Pharmaceuticals (Nasdaq: OSMT) will announce its 2020 third quarter financial results on November 10, 2020, after the U.S. financial markets close. A conference call will be held at 4:30 p.m. ET on the same day, featuring CEO Brian Markison, COO JD Schaub, and CFO Andrew Einhorn. Investors can join via toll-free number (866) 672-5029 for U.S. callers or (409) 217-8312 for international participants, using Conference ID: 4356477. A live webcast will also be available on the Osmotica website.
- None.
- None.
BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 third quarter financial results on Tuesday, November 10, 2020, after the close of the U.S. financial markets.
Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows:
| Date | Tuesday, November 10, 2020 | |
| Time | 4:30 p.m. ET | |
| Toll free (U.S.) | (866) 672-5029 | |
| International | (409) 217-8312 | |
| Conference ID | 4356477 | |
| Webcast (live and replay) | www.osmotica.com under the “Investor & News” section |
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations.
Osmotica has operations in the United States, Argentina, and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
When will Osmotica Pharmaceuticals announce its third quarter financial results for 2020?
What time is the conference call for Osmotica Pharmaceuticals third quarter results?
How can I join the Osmotica Pharmaceuticals conference call?
Will there be a webcast available for the Osmotica Pharmaceuticals conference call?
